title: [Tend to second-line therapy in lung cancer].
abstract: Second-line chemotherapy has been established for non-small-cell lung cancer(NSCLC)and sensitive relapsed small cell lung cancer(SCLC).Molecular targeted drugs, such as EGFR- and ALK-inhibitors, have improved survival outcome remarkably in patients with NSCLC harboring EGFR mutations or EML4-ALK fusion proteins.In addition, targeted drugs that may overcome T790M-mediated EGFR-TKI resistance have been developed, and the development of future therapeutic strategies is anticipated.On the other hand, molecular targeted drugs against SCLC have not yet been developed.
authors.affiliation: Division of Thoracic Oncology, Shizuoka Cancer Center.
authors.forename: Haruki
authors.initials: H
authors.lastname: Kobayashi
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Takahashi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D066246:ErbB Receptors / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009154:Mutation; D012008:Recurrence
chemical_list: D000970:Antineoplastic Agents; C512478:EGFR protein, human; D066246:ErbB Receptors